Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Phenobarbital

Related Products

Hot Products

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Name

Phenobarbital

EINECS 200-007-0
CAS No. 50-06-6 Density 1.234 g/cm3
PSA 75.27000 LogP 1.35800
Solubility < 0.01 g/100 mL at 14 °C in water Melting Point 174 °C
Formula C12H12N2O3 Boiling Point 374.4°C (rough estimate)
Molecular Weight 232.239 Flash Point 11 °C
Transport Information UN 2811 Appearance Crystalline Solid
Safety 53-36/37-45 Risk Codes 25-40-43-61
Molecular Structure Molecular Structure of 50-06-6 (Phenobarbital) Hazard Symbols ToxicT
Synonyms

Barbituricacid, 5-ethyl-5-phenyl- (8CI);5-Ethyl-5-phenylbarbituric acid;5-Phenyl-5-ethylbarbituric acid;Adonal;Agrypnal;Amylofene;Barbenyl;Barbiphenyl;Barbipil;Barbita;Barbivis;Blu-phen;Cratecil;Dormiral;Doscalun;Duneryl;Eskabarb;Etilfen;Euneryl;Fenemal;Fenemal recip;Gardenal;Gardepanyl;Hysteps;Lepinal;Lepinaletten;Liquital;Lixophen;Lubergal;Luminal;NSC 128143;NSC 9848;Neurobarb;Noptil;Nunol;Phenaemal;Phenemal;Phenobar;Phenobarbital;Phenobarbitone;Phenobarbituric acid;Phenoluric;Phenonyl;Phenylethylbarbituric acid;Phenylethylmalonylurea;Phenyral;Phob;Sedonal;Sedophen;Sevenal;Solfoton;Somonal;StentalExtentabs;Talpheno;Teolaxin;Triphenatol;Versomnal;A0038 Cyclic-peoxide-containing acid 3;

Article Data 33

Phenobarbital History

The first barbiturate drug, barbital, was synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering at Bayer. By 1904 several related drugs, including Phenobarbital (CAS NO.50-06-6),had been synthesized by Fischer. Phenobarbital (CAS NO.50-06-6) was brought to market  in 1912 by the drug company Bayer using the brand Luminal. It remained a commonly prescribed sedative and hypnotic until the introduction of benzodiazepines in the 1950s.Phenobarbital's soporific, sedative and hypnotic properties were well known in 1912, but nobody knew it was also an effective anticonvulsant.
Between 1934-1945 Phenobarbital (CAS NO.50-06-6) under the brand name Luminal, was used by German doctors under the Nazi party endorsed policy of eugenics to remove children born with disease or deformities from the population so that they would not suffer. Many of the medical staff involved were later to transfer to Nazi hospitals. Phenobarbital (CAS NO.50-06-6) was used to treat neonatal jaundice by increasing liver metabolism and thus lowering bilirubin levels. In the 1950s, phototherapy was discovered, and became the standard treatment.

Phenobarbital Consensus Reports

EPA Genetic Toxicology Program. IARC Cancer Review: Group 2B IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 (1987),p. 313.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Sufficient Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 (1987),p. 313.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Inadequate Evidence IMEMDT    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 13 (1977),p. 157.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) .

Phenobarbital Specification

The Phenobarbital, with the CAS registry number 50-06-6 and EINECS registry number 200-007-0, has the IUPAC name of 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione. It is a kind of crystalline solid, and belongs to the following proudct categories: Aromatics; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals. And the molecular formula of this chemical is C12H12N2O3. What's more, it should be stored at 2-8°C.

The physical properties of Phenobarbital are as followings: (1)ACD/LogP: 1.67; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.67; (4)ACD/LogD (pH 7.4): 1.47; (5)ACD/BCF (pH 5.5): 10.83; (6)ACD/BCF (pH 7.4): 6.93; (7)ACD/KOC (pH 5.5): 191.18; (8)ACD/KOC (pH 7.4): 122.28; (9)#H bond acceptors: 5; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 2; (12)Polar Surface Area: 57.69 Å2; (13)Index of Refraction: 1.541; (14)Molar Refractivity: 59.21 cm3; (15)Molar Volume: 188.1 cm3; (16)Polarizability: 23.47×10-24cm3; (17)Surface Tension: 43.3 dyne/cm; (18)Density: 1.234 g/cm3.

Preparation of Phenobarbital: It can start with the condensation of benzyl cyanide with diethylcarbonate in the presence of sodium ethoxide, and the result is α-phenylcyanoacetic ester. Alkylation of the ester needs ethyl bromide, and gives α-phenyl-α-ethylcyanoacetic ester, which is further converted into the 4-iminoderivative upon treatment with urea. And acidic hydrolysis of the resulting product gives phenobarbital.

Preparation of Phenobarbital can start with the condensation of benzyl cyanide with diethylcarbonate in the presence of sodium ethoxide, and the result is α-phenylcyanoacetic ester. Alkylation of the ester needs ethyl bromide, and gives α-phenyl-α-ethylcyanoacetic ester, which is further converted into the 4-iminoderivative upon treatment with urea. And acidic hydrolysis of the resulting product gives phenobarbital.

Uses of Phenobarbital: It is widely used as a anticonvulsant . And it is often used for the treatment of acute withdrawal from benzodiazepines. What's more, it also inhibits glutamate induced depolarizations.

You should be cautious while dealing with this chemical. It is toxic if swallowed, and may cause sensitization by skin contact. It has risk of serious damage to eyes, and it may also cause harm to the unborn child. Therefore, you had better take the following instructions: Avoid exposure - obtain special instruction before use. Wear suitable protective clothing and gloves, and in case of accident or if you feel unwell, seek medical advice immediately (show label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O=C1NC(=O)NC(=O)C1(c2ccccc2)CC
(2)InChI: InChI=1/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
(3)InChIKey: DDBREPKUVSBGFI-UHFFFAOYAB

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LDLo oral 125mg/kg (125mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
cat LDLo subcutaneous 125mg/kg (125mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
child TDLo oral 10mg/kg (10mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA
American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976.
child TDLo oral 20mg/kg/I (20mg/kg) SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE

BEHAVIORAL: ATAXIA

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)
Clinical Pediatrics Vol. 31, Pg. 252, 1992.
dog LD50 oral 150mg/kg (150mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Schweizerische Medizinische Wochenschrift. Vol. 85, Pg. 305, 1955.
dog LDLo subcutaneous 150mg/kg (150mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
frog LDLo subcutaneous 500mg/kg (500mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1289, 1935.
guinea pig LD50 oral 130mg/kg (130mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 91, Pg. 437, 1952.
human TDLo oral 18mg/kg (18mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
JAMA, Journal of the American Medical Association. Vol. 116, Pg. 700, 1941.
infant TDLo intramuscular 50mg/kg (50mg/kg) BEHAVIORAL: COMA Pediatrics. Vol. 77, Pg. 848, 1986.
man LDLo oral 6485ug/kg/2W- (6.485mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Annals of Internal Medicine. Vol. 13, Pg. 1243, 1940.
mouse LD50 intramuscular 175mg/kg (175mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 23, Pg. 2215, 1981.
mouse LD50 intraperitoneal 88mg/kg (88mg/kg)   Pharmazie. Vol. 52, Pg. 926, 1997.
mouse LD50 intravenous 218mg/kg (218mg/kg) PERIPHERAL NERVE AND SENSATION: LOCAL ANESTHETIC Archives Internationales de Pharmacodynamie et de Therapie. Vol. 191, Pg. 405, 1971.
mouse LD50 oral 137mg/kg (137mg/kg)   Pharmaceutical Chemistry Journal Vol. 10, Pg. 41, 1976.
mouse LD50 subcutaneous 228mg/kg (228mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 477, 1980.
rabbit LD50 intravenous 187mg/kg (187mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1168, 1983.
rabbit LD50 oral 185mg/kg (185mg/kg)   Neuropatologia Polska. Vol. 15, Pg. 545, 1977.
rabbit LDLo intraperitoneal 150mg/kg (150mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 44, Pg. 325, 1932.
rabbit LDLo subcutaneous 150mg/kg (150mg/kg)   Journal of the American Chemical Society. Vol. 45, Pg. 243, 1923.
rat LC inhalation > 4100ug/m3/4H (4.1mg/m3) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BLOOD: OTHER CHANGES
Toksikologicheskii Vestnik. Vol. (1), Pg. 39, 2000.
rat LD50 intraperitoneal 110mg/kg (110mg/kg)   French Medicament Patent Document. Vol. #7157M,
rat LD50 intravenous 209mg/kg (209mg/kg)   Archives of Toxicology. Vol. 40, Pg. 211, 1978.
rat LD50 oral 162mg/kg (162mg/kg)   Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971.
rat LD50 rectal 284mg/kg (284mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: GENERAL ANESTHETIC
Anesthesia and Analgesia Vol. 46, Pg. 395, 1967.
rat LD50 subcutaneous 200mg/kg (200mg/kg)   Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 152, Pg. 341, 1930.
women LDLo oral 25272ug/kg/13 (25.272mg/kg) BEHAVIORAL: COMA

SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"
Canadian Medical Association Journal. Vol. 33, Pg. 635, 1935.
women TDLo oral 46mg/kg (46mg/kg) BEHAVIORAL: COMA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Clinical Pediatrics Vol. 24, Pg. 678, 1985.